THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
10 août 2020 16h01 HE | Abeona Therapeutics Inc.
Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO-102 for MPS IIIA Data from RDEB and MPS III programs...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
10 juil. 2020 07h30 HE | Abeona Therapeutics Inc.
EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEBLiterature review of 65 studies confirms and expands understanding of substantial...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
09 juil. 2020 07h30 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
08 juil. 2020 07h30 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
18 juin 2020 07h30 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to...
Spray-On Gene Therapy With RenovaCare SkinGun™ in New Study Underway at King’s College London
30 mars 2020 08h32 HE | RenovaCare, Inc.
ROSELAND, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the...
Abeona Therapeutics.jpg
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
17 mars 2020 07h30 HE | Abeona Therapeutics Inc.
Majority of potential study participants have been pre-screened EB-101 successfully manufactured at Abeona and transplanted at Stanford University Medical Center NEW YORK and CLEVELAND, March 17,...
Abeona Therapeutics.jpg
Abeona Therapeutics leitet klinische Phase-3-Schlüsselstudie zur Beurteilung der Gentherapie EB-101 bei rezessiver dystropher Epidermolysis bullosa (RDEB) ein
13 janv. 2020 15h32 HE | Abeona Therapeutics Inc.
Die Studie ist für die Rekrutierung geöffnet und das Patientenscreening ist an der Stanford University angelaufen Das Unternehmen erwartet die Behandlung des ersten Patienten im ersten Quartal 2020 ...
Abeona Therapeutics.jpg
Abeona Therapeutics lance un essai clinique pivot de phase 3 évaluant la thérapie génique EB-101 pour l'épidermolyse bulleuse dystrophique récessive
13 janv. 2020 15h32 HE | Abeona Therapeutics Inc.
Les inscriptions à l'étude sont ouvertes et la sélection des patients est en cours à l'Université de Stanford La société s'attend à ce qu'un premier patient soit traité au cours du premier trimestre...
Abeona Therapeutics.jpg
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
13 janv. 2020 09h00 HE | Abeona Therapeutics Inc.
Study open for enrollment and patient screening underway at Stanford University Company expects first patient to be treated in the first quarter of 2020 EB-101 manufactured at Abeona facility in...